Table I.
Hot-plate test latency time results, by treatment group.*
| Time (min) |
Group 1 (n = 8) |
Group 2 (n = 8) |
Group 3 (n = 8) |
Group 4 (n = 8) |
Group 5 (n = 8) |
P Value |
|---|---|---|---|---|---|---|
| Median sec (minimum–maximum) | ||||||
| Basal | 13 (7–17) | 12 (8–15) | 10 (9–13) | 13 (8–17) | 13 (7–16) | |
| 30 | 15 (11–22) | 20 (12–24) | 25 (14–29)† | 17 (12–25) | 14 (7–19) | 0.0001 |
| 60 | 15 (7–24) | 20 (11–25) | 24 (13–28)† | 16 (8–18) | 14 (6–21) | 0.0004 |
| 90 | 14 (11–23) | 17 (13–24) | 17 (12–25) | 15 (9–17) | 13 (8–18) | NS |
| 120 | 13 (8–23) | 13 (8–23) | 15 (10–25) | 17 (10–20) | 14 (10–19) | NS |
| 150 | 13 (11–18) | 12 (10–24) | 15 (12–23) | 17 (10–21) | 13 (8–16) | NS |
| 180 | 14 (8–17) | 15 (11–20) | 16 (12–24) | 18 (11–24) | 14 (11–22) | NS |
| 210 | 14 (7–19) | 13 (11–19) | 14 (10–22) | 15 (12–18) | 15 (8–22) | NS |
| 240 | 13 (11–16) | 12 (11–16) | 14 (12–19) | 16 (12–19) | 14 (10–19) | NS |
NS = Not significant.
⁎
Group 1: sham, Group 2: perineural levobupivacaine (0.2 mL 0.5% solution) and subcutaneous saline, Group 3: perineural levobupivacaine (0.2 mL 0.5% solution) plus dexmedetomidine (0.2 mL 0.5% levobupivacaine + 20 µg/kg dexmedetomidine) and subcutaneous saline, Group 4: perineural saline and subcutaneous dexmedetomidine, Group 5: perineural saline and subcutaneous saline.
†
Group 2 versus Group 3 (P < 0.01).